In the BioHarmony Drug Report Database
Ibandronate
Boniva, Bondronat, Bonviva (ibandronic acid) is a small molecule pharmaceutical. Ibandronic acid was first approved as Boniva on 1996-06-25. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, and hypercalcemia amongst others. It is known to target farnesyl pyrophosphate synthase. Boniva’s patent is valid until 2023-05-06 (FDA).
Trade Name
|
Bondronat, Bonviva |
|---|---|
Common Name
|
ibandronic acid |
ChEMBL ID
|
CHEMBL997 |
Indication
|
bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, hypercalcemia, neoplasm metastasis, neoplasms by site, neoplastic processes, postmenopausal osteoporosis, water-electrolyte imbalance, wounds and injuries |
Drug Class
|
Androgens |
Image (chem structure or protein)